Delivery Order SPE2DB20D1100-SPE2DB25FE3T6
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. The contract reflects a firm fixed price arrangement with an ultimate completion date of August 20, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order was competitively awarded without set-aside designation, consistent with the vendor's track...
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 22, 2025, for the supply of Actemra 162 mg/0.9 mL syringes valued at $36,593.17. This competitively awarded, firm fixed-price delivery order is scheduled for completion by July 23, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The contract does not utilize a set-aside designation and falls under the company's existing Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $3,328.29 to AmerisourceBergen Drug Corp on July 30, 2025, for the supply of Actemra 162 mg/0.9 ml syringes. This firm fixed-price delivery order is scheduled for completion by July 31, 2025, and will be performed at AmerisourceBergen's Conshohocken, Pennsylvania facility. The award was made through open competition with no set-aside designation, reflecting the contractor's demonstrated capability to meet federal pharmaceutical...
- AmerisourceBergen Drug Corp was awarded a delivery order by the Defense Logistics Agency (DLA) on August 28, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This competitively awarded, non-set-aside contract has a ceiling value of $7,570.81 and a firm fixed price structure, with an ultimate completion date of August 29, 2025. The product will be delivered to Conshohocken, Pennsylvania, where AmerisourceBergen's corporate office is headquartered. This delivery order operates as a child...
- The Defense Logistics Agency awarded a delivery order valued at $11,336.48 to AmerisourceBergen Drug Corp for the supply of Actemra 162 mg/0.9 ml syringes, with a completion date of August 20, 2025. This competitively awarded, firm fixed-price contract carries no set-aside designation and represents a direct fulfillment order under AmerisourceBergen's broader contract vehicle with DLA. The pharmaceutical product will be delivered to the contractor's location in Conshohocken, Pennsylvania,...
- The Defense Logistics Agency awarded a $3,729.39 delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Actemra 200 mg/10 mL vials. The contract, which is a firm fixed price delivery order with an ultimate completion date of August 20, 2025, represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX). This award was made through open competition with no set-aside designation, reflecting...
- The Defense Logistics Agency awarded a delivery order valued at $3,386.42 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Actemra 400 mg/20 ml vials. This firm fixed-price delivery order is scheduled for completion by September 2, 2025, and will be performed at AmerisourceBergen's facility in Conshohocken, Pennsylvania. The contract was competitively awarded with no set-aside designation. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 4, 2025, for the supply of Actemra 162 mg/0.9 mL syringes, with a ceiling value of $23,369.56 and a firm fixed price structure. The delivery order is non-set-aside and represents a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999.999 billion prime vendor agreement running through December 2026. Performance is scheduled for...
- AmerisourceBergen Drug Corp was awarded a delivery order contract by the Defense Logistics Agency (DLA) on July 26, 2025, for the supply of ACTEMRA 162 mg/0.9 mL syringes valued at $5,945.97 with a firm fixed price structure. The contract specifies a completion date of July 28, 2025, and will be performed at the company's corporate office location in Conshohocken, Pennsylvania. This is an unrestricted, competitively awarded delivery order with no set-aside designation. This delivery order is...
- The Defense Logistics Agency awarded a $3,779.36 delivery order to AmerisourceBergen Drug Corp on August 13, 2025, for the supply of Actemra 162 mg/0.9 mL syringes. This non-set-aside, firm fixed price contract is scheduled for completion by August 14, 2025, with performance taking place at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider, fulfills this order as a child delivery order...
- SPE2DB20D1100Indefinite Delivery Contract
- SPE2DB20D1100-SPE2DB25FE3T6Delivery Order
The Defense Logistics Agency (DLA) awarded a delivery order valued at $2,287.88 to AmerisourceBergen Drug Corp on August 29, 2025, for the supply of Actemra 162 mg/0.9 ml syringes. This is a firm fixed price delivery order with a completion date of September 2, 2025, with no set-aside designation applied. The contract represents a competitive award under DLA's broader pharmaceutical supply framework, with performance at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999,999,999.00 and extending through December 2026. The parent IDC serves as a comprehensive global pharmaceutical support vehicle enabling the company to supply a wide range of pharmaceutical products and medical supplies to military healthcare programs worldwide. AmerisourceBergen's federal contract portfolio demonstrates its established capability as a critical vendor for military and veteran healthcare systems, delivering specialty medications, brand-name and generic drugs, vaccines, and related medical supplies across multiple therapeutic domains to support Defense Health Agency and other federal healthcare customers.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $2.3k | 8/29/25 |